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METHODS:We identified patients hospitalized for ACS-PCIwith continuous enroll-
ment in MarketScan databases for  6 months before admission and 60 days after
discharge, without history of stroke or transient ischemic attack. Pharmacy dis-
pensing records were searched to determine the first, if any, thienopyridine dis-
pensed within 60 days after discharge. Demographic characteristics, medical and
treatment history during the 6 months prior to the hospitalization were compared
for patients filling prescriptions of clopidogrel, prasugrel, or neither. RESULTS: A
total of 39,953 patients were eligible for the analysis; 29,900 (74.8%) filled clopi-
dogrel prescriptions, 5,243 (13.1%) filled prasugrel prescriptions, and 4,810 (12.0%)
filled no thienopyridines within 60 days after ACS-PCI. Patients filling prasugrel
were younger (mean age 55.9 vs. 60.9, P0.0001), more likely to be male (78.9% vs.
72.2%, P0.0001), and from theMidwest (38.3% vs. 33.9%, P0.0001) comparedwith
clopidogrel users. Patients filling prasugrel had higher percentage of ST elevation
myocardial infarction (STEMI) during the hospitalization than clopidogrel (40.7%
vs. 33.3%, P0.0001). Charlson Comorbidity Index (CCI) was low (0-1) for more
prasugrel than clopidogrel users (85.9% vs. 80.2%, P0.0001); prevalence of many
comorbidities was also lower among prasugrel users. In contrast, patients with
no thienopyridine after ACS-PCI were older (mean age 62.2), more likely to have
high (2) CCI (25.5%, P0.0001), less likely to have STEMI (25.6%, P0.0001) and
a higher prevalence of many comorbidities than patients taking clopidogrel.
CONCLUSIONS: Patients filling no thienopyridine prescription following ACS-PCI
were older and had more comorbidities than patients filling clopidogrel prescrip-
tions. Patients filling prasugrel prescriptions tended to be younger and have fewer
comorbidities than thosewith clopidogrel, whichmay reflect lower bleeding risk of
this ACS-PCI population.
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OBJECTIVES: The Institute of Medicine estimates that 17 years elapse between
phase III study completion and a new treatment’s full integration into clinical
practice. Recognizing that clinical practice guidelines (CPGs) are an important
source of information for clinicians as they integrate new treatments into routine
practice, we sought to understand the time it takes for CPGs to release recommen-
dations on novel therapies.METHODS:We conducted case analyses in CVD, a high
burden therapeutic area with numerous treatment options and well-established
guideline development processes. We selected 4 antithrombotic therapies intro-
duced over the past 15 years: ticagralor, dabigatran, prasugrel, and clopidogrel. For
each drug we captured key dates to assess the time interval between release of
registration trial data and inclusion in CPGs. The guidelines explored were the
leading US and EU references for the relevant indication, and “inclusion in CPGs”
referred to the presence of a class- or product-specific recommendation (October,
2011). RESULTS: Across 3 products, the interval from data release to CPG inclusion
ranged from 4 to 18 months (mean 25 months) in the United States, and 13 to 46
months (mean 29 months) in the EU. Limitations of the analysis include no dab-
igatran-relevant recommendations to date in the EU guidelines reviewed, and no
ticagrelor-relevant recommendations to date in the US guidelines reviewed. Addi-
tionally, ticagralor appeared in EU guidelines 2 months prior to regulatory
approval. CONCLUSIONS: Our observational analysis shows that the time it takes
for CPGs to incorporate new therapies varies, even within the same therapeutic
area and the same guideline developers. Future research will expand this inquiry
into other therapeutic areas and also explore various product- and market-level
factors that may affect time to CPG inclusion. While guidelines organizations work
to streamline review processes, manufacturers should improve their understand-
ing of revision timelines to maximize the impact of data release.
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BACKGROUND: Several HTA agencies around the world have published compre-
hensive HTA guidelines to help authors adhere to the principles and methods of
HTA. Many have also embraced recent methodological developments in compar-
ative effectiveness research, such as indirect and mixed treatment comparisons,
and recommend their use when head-to-head evidence is not available. Differ-
ences exist, however, between these guidelines and how these are interpreted
especially in terms of evidential andmethodological requirements.OBJECTIVES:A
case study was conducted to evaluate the impact of different evidence synthesis
methods, as recommended by HTA agencies, on the effectiveness and cost-effec-
tiveness of new medicines in the UK.METHODS: Using a reconstructed economic
model based on the NICE technology appraisal for ticagrelor (TA236), different
evidence base andmeta-analysis methods were used, in accordance with country-
specific HTA guidelines and existing assessment reports (i.e. CADTH (Canada), CVZ
(The Netherlands), PBAC (Australia)), to estimate the relative effectiveness and
ICER of ticagrelor compared to clopidogrel and prasugrel for the treatment of acute
coronary syndromes. Differences in evidence identification and study selection,
evidence synthesis, and clinical effectiveness model inputs were evaluated.
PRELIMINARY RESULTS: Whilst CADTH and CVZ included a published indirect
comparison between ticagrelor and prasugrel in their evidence review; NICE re-
garded the use of indirect evidence as inappropriate and PBAC did not consider
prasugrel as a relevant comparator. Such differences in clinical evidence consid-
erations, and methods used call into question recent efforts to promote interna-
tional HTA harmonisation. In addition, the uncertainty in the results estimated in
our model demonstrated the importance of appropriately defining and measuring
(relative) efficacy inputs inHTA to ensure optimal health policies are implemented.
CONCLUSIONS: Since 2011, ticagrelor is recommended for use in the United King-
dom; however, the Canadian Expert Drug Advisory Committee recommended that
ticagrelor not be listed in publicly funded drug plans in Canada.
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OBJECTIVES: An effective measurement tool is required to assess the economic
effects of acute ischemic stroke (AIS) imaging interventions and to determine how
themagnitude of AIS-attributable impairment changes over time so that thesemay
be incorporated into economic analyses. The modified Rankin scale (mRS) is the
most prevalently used measure of AIS outcomes however it has generated skepti-
cism, concern and confusion regarding the results of stroke outcome studies. This
study assesses all clinimetric properties of the mRS and outlines improvement
opportunities.METHODS: ThemRS was analyzed using a set of clinimetric assess-
ment instruments including the Bombardier sensibility assessment tool and Bea-
ton responsiveness guidelines. Each clinimetric domain was evaluated, namely,
measure development; item generation; measure administration; sensibility; reli-
ability; validity; and responsiveness. RESULTS: The mRS displayed many short-
comings including: 1) vague definition of concept measured; 2) lack of item gener-
ation rigor; 3) compromised face validity; 4) no evidence of validity and reliability
among AIS patients; and 5) inadequate study of responsiveness due to arbitrary
choices of clinically important differences for comparison scales. CONCLUSIONS:
The mRS is a flawed instrument for estimating AIS outcomes. Minimally, high
quality, adequately powered de novo assessments of its validity, reliability and
responsiveness should be undertaken. Preferably, a new AIS outcome measure to
measure should be developed by following the detailed recommendations within
each of the clinimetric properties sections of this assessment. This ideal AIS out-
come measure could be applied to AIS outcome studies resulting in a facilitation,
rather than obfuscation, of efforts to reduce the burden of AIS.
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OBJECTIVES: Item response theory (IRT) combined with computer adaptive testing
(CAT) can improve assessment of self-reported measures by reducing measure-
ment error and respondent burden. We previously used IRT to develop an item
bank of health impact on role functioning (RF) in 3 areas (family, social, occupa-
tional).We tested the validity of a simulated 4-itemCATbased on 10 items fromour
previously-developed bank in acute coronary syndrome (ACS) patients and com-
pared its performance with 2 established SF-36 scales - role physical (RP) and role
emotional (RE).METHODS: Adults (n759) in Worcester, MA and Macon, GA were
interviewed during an ACS hospitalization for the TRACE-CORE (Transitions, Risk,
and Actions in Coronary Events: Center for Outcomes Research and Education)
study. Ten questions from the RF item bank were administered; we assessed their
construct validity using factor analysis. We produced a 4-item CAT using simula-
tions with the 10-item data. We compared score accuracy and ability to discrimi-
nate between groups based on levels of self-reported general health (SF-36), de-
pression (PHQ9) and anxiety (GAD7) for the 10 items, the CAT and the SF-36 role
scales. RESULTS: Average patient age was 61.111.6 years, with 64.8% men, 76%
non-Hispanicwhite, 13%African-American.We confirmed the construct validity of
the 10-bank items. The CAT improvedmeasurement precision and expandedmea-
surement range by 0.5 SD versus the SF36 RP. All measures discriminated across
levels of general health, depression, and anxiety (p 0.0001). The instruments
showed high agreement on the mean score for each subgroup, but the CAT scores
had lower SDs. Relative validity coefficients suggest that CAT discriminated better
than the SF36 RP and RE scales. CONCLUSIONS: Use of CAT improved assessment
accuracy and discrimination among pre-defined groups, suggesting modern psy-
chometric approach leads to practical advantages in assessment. Results will fur-
ther be validated with clinical criteria and predictive analysis.
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INFORMATION IN THE UK: PRELIMINARY RESULTS FROM WASPS (WALES
SAIL  PRO STUDY)
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OBJECTIVES: As demand for real-world data increases, the need to adopt more
time and cost-efficient research methods will grow. Direct-to-patient studies (di-
rect patient recruitment without physician sites) are a novel, efficient approach
gaining proof in the United States. This study’s objective was to deploy a direct-to-
patient observational study in the UK including both patient-reported and elec-
tronic health data. METHODS: In October/November 2011, UK MediGuard.org
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